Sarna S, Bhola R K, Sodhi A
Department of Zoology, Gauhati University, Guwahati, India.
Pol J Pharmacol Pharm. 1988 May-Jun;40(3):295-302.
Cis-dichlorodiammine platinum (II) (cisplatin) has been successfully used in experimental immunotherapy of syngeneic transplantable fibrosarcoma in mice. Incubation of fibrosarcoma cells with cisplatin in vitro causes release of sialic acid from tumor cells. The estimation of sialic acid in the supernatant have shown a difference in the release of sialic acid from the tumor cells with different concentrations of cisplatin. The removal of sialic acid from fibrosarcoma cells after cisplatin treatment suggests a possible exposure of certain antigenic sites on the tumor cell surfaces. Such membrane changes may be responsible for the increased antigenicity of fibrosarcoma cells.
顺二氯二氨铂（II）（顺铂）已成功用于小鼠同基因可移植纤维肉瘤的实验性免疫治疗。体外将纤维肉瘤细胞与顺铂孵育会导致肿瘤细胞释放唾液酸。对上清液中唾液酸的估计表明，不同浓度顺铂作用下肿瘤细胞释放唾液酸存在差异。顺铂处理后纤维肉瘤细胞中唾液酸的去除表明肿瘤细胞表面某些抗原位点可能暴露。这种膜变化可能是纤维肉瘤细胞抗原性增加的原因。
